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Dopexamine hydrochloride Is a new synthetic catcchol that offers
a unique profile of adrenergic and dopaminergic activity . In this
multicenter, parallel design, placebo-controlled study, 45 patients
with functional class III or IV chronic congestive heart failure
were randomized to receive a placebo infusion or me of three
different doses of dopexamine . After a 2-h dose titration segue-
patients received a 6-h constant dose infusion . During this 6-h
period, dopexamine was infused at rates of t, 2 and 4 pg)kg body
weight per min in the low, intermediate and high dose groups,
respectively.
In patients receiving high dose infusion, dopexamine produced
a 70% increase in cardiac index associated with a 43% decrease in
systemic vascular resistance and 21%r increase in heart rate (p 'C
0.05 vs . placebo for all three varieties) . There was a trend (p =
NS) toward a moderate increase in cardiac index at low and
intermediate doses . In patients randomized to receive dopexam-
The treatment of congestive heart failure continue' to pose
numerous challenges for the clinician . Whereas orally ad-
ministered diuretic drugs. vasodilators and digitalis are fre-
quently used in the long-term management of patients with
impaired left ventricular function . there are times when
hemodynamic instability or clinical dccvrnpensaliun man-
dates more aggressive therapy with intravenou , agents .
Dopexamine hydrochloride is a new synthetic agent that
combines a unique profile of adrenergic and dopaminergic
agonist activity . Animal studies (1 .2) employing receptor
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ins, right atria!, systemic arterial, pulmonary artery and pulmo-
nary capillary wedge pressures showed minimal change from
baseline and did not differ statistically from the placebo response .
Very few patients developed adverse reactions related to dopex-
ne, although five patients randomized to receive high dose and
three patients randomized to receive intermediate dose dopexam
.
ine required dose reduction because hemodynamic variables ex-
ceeded arbitrary safety limits or the patients developed symptoms
related to the study medication .
Dopexamine in higher doses effectively increases cardiac index
in association with a reduction in systemic vascular resistance
.
Additional clinical studies are indicated tee evaluate the merits
of
dopexamine in comparison with other isotropic and vasodilator
medications .
(J Am Coll Cardiol 1991;18:383. 0)
blockade hove demonstrated that dopexamine exerts 60
times more beta,-adrenergic activity . '/e less beta s -adrener-
gic
activity.
'/ less DA,-dopaminergic activity and /l to '/e
less pre iunctional DA,-dopaminergic activity in comparison
with dupr nine. Unlike dopamine. dopexamine has no sub-
stantial effect on alpha-adrenergic receptors.
Dopexamine has been shown (3-14) to improve cardiac
performance
in
patients with congestive heart failure or after
cardiac surgery. Most of these reports have dealt with small
numbers of patients and have utilized protocols that were
unmasked and lacked a placebo-controlled, parallel design,
because there is often ennside-able spontaneous variation in
hemodynamic variables in hospitalized pati^r's . it is difficult
to accurately analyze the specific clinical and hemodynamic
features of dopexamine hydrochloride without a placebo
control group ( 15.16) . In addition, the crossover clinical trial
desigr has bets subject to criticism (17) and presents limi-
tations in the accurate evaluation of a study medication .
This report represents the first multicenter, randomized .
parallel . placebo-controlled study of the short-term hemody-
namic effects of dopexamine in various doses . The primary
0735-1097191/53.54
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Table I . Baseline Clinical Characteristics of the Fnur Patient Groups
Wilyrurosemidednselmgr 134x127
objective of this study was to compare the hemodynrunic
response of Patients with severe congestive heart failure
randomized Ia teccive a 6 h constant infusion of one of three
different doses of dopexamine or placebo
. Determination of
urinary output and adverse reactions was also a primary
objective of the study .
Methods
This study was designed as a phase lit multicenter trial .
Approval was obtained from each ceeler's Institutional
Review Sward before implementation : the protocol . All
patients gave informed, written consent Eefore entry into the
study.
Inclusion and exclusion criteria. Adults with New York
Heart Association functional class III or IV congestive heart
failure were eligible for study if preliminary hemodynamic
investigation revealed a cardiac index of s2
.5 liters/min
per m 2 and a pulmonary capillary wedge
pressure of
15 mm Hg. Patients wore excluded if they had cardiogenic
shock, severe unstable angina, recent myocardial infarction,
severe stenotic valvular heart disease, potentially life-
threatening cardiac arrhythmias, rest eachycardia >120
beats/min or atrial fibrillation with average ventricular re-
sponse >100 leatslmin or severe concurrent noncardiac
disease .
Study patients- The study group consisted of 45 patients
recruited from eight different centers The investigation was
126 c 79 138 rt 142 133 z 79
'Values are mean values SD, all other values are pa-s. There was no signfieuel dreaenee in any or the
value, amoeg the four groups
. ACE =
angioknsimconarraru enzyme;
MI =
my-dal
infarction ; NYH. CtiF
class -= New York Heart Association cmrgestiue
heart fsttre functional dassidcatisn .
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initially designed such that each institution would enroll six
patients . Because of limited enrollment at certain centers
.
the majority of prdients were studied at three participating
institutions, each of which enrolled >_10 patients . Five
centers entered six patients or less
. Baseline clinical char-
acteristics of study patients are listed in Table I . One patient
randomized to the placebo group was dependent on a
permanent fixed rate
ventricular
pacemaker. The cardiac
rhythm in one patient receiving low dose dopexamine was
atria] flutter with variable block .
Shay desipl. All patients were admitted to a coronary
intensive care unit for the duration of the trial . A balloon-
lipped (Swan-Ganz) catheter was positioned in the pulmo-
nary artery by standard sterile technique. Arterial pressure
was monitored directly with a radial or brachial artery
catheter. Before randomization, patients received an 8-h
infusion of 5% dextrose in water at a rate of 30 ml/h. Total
fluid intake and output were recorded over this period .
During the final hour of the 9-h baseline period, hemody-
namic variables were measured at 15-min intervals until
cardiac output, heart rate and pulmonary capillary wedge
pressures for two sets of measurements were within 10%
agreement . Cardiac output (CO) was measured by thermodi-
lution technique and heart rate (HR) and mean right atria)
(RAP), systemic arterial, pulmonary artery (MPAP) and
pulmonary capillary wedge (PCWP) pressures were re-
corded at each limo interval, Cardiac Output measurements
were peltformed in triplicate with use of 10 ml of ice-cold 5%
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dextrose in water as the indicator . Cardiac index iCl,
systemic (SVR) and pulmonary IPVRI vascular resistance
and stroke volume ISVI) and stroke work (SWI1 index were
calculated with the following formulas; Cl Iliterslmin per m'- )
CO/BSA, where BSA = body surface area; SVR
(dynes , trem 'l = 80 IMAP - RAP)ICO, where MAP mean arterial pressure
; PVR = 80IMPAP - PCWPI+COI
and SVI (mUm 1) - CIMR and SWI Ig mlmtt = (MAP -
PCWP) (SVI) (09136). A count of ventricular premature
beats over 3 conseeulsvc man was also obtained at each
recording interval,
Each patient was then randomized to receive an infusion
of placebo. low dose dopcxaminc 41 pgflkg per min), inter-
mediate dose dnpexamine 12 pglkg per mi,
•I
or hi(-h dote
dopexamme (4 µglkg pet ;nin)- Infusions were continued for
8 h and consisted of a 2-h dose titration sequence and a 6-h
constant rate infusion, During the dose titration period, an
increase in drug infusion was achieved by increasing the
infusion rate . At the start of the dose titration peried
. drug
infusions were initiated at rates of 0-25. 0.5 and I cg4cg per
min for the low, intermediate and high dose groups
.. respec-
tively . The dose was doubled at 30-min intervals until the
constant rate infusion dose was reached . and hemodynamic
measurements were obtained every 30 min. Incremental
dose titration was slopped and the infusion rate decreased by
50% in the event of lachycardia with heart rate >20%, of
baseline or an absolute value of 140 heatslmin, a change in
pulmonary capillary wedge pressure exceeding baseline by
10 mm Hg or decreasing below an absolute value of
10 mm Hg. nausea, tremor or other severe adverse reac-
lions, These variables were thought to be representative of
safety guidelines commonly followed with the use of inotro .
pie and vasodilator medications in patients with congestive
heart failure .
The dose infused 41 the end of the 2-h dose titratiun
sequence was continued far an additional 6 h . he constant
rate infusion was discontinued in the event of significant
adverse hemodynamic or clinical effects. Hemodynamic
measurements were obtained at 2-h intervals during the 6-h
constant rate infusion . Total intake and output were re-
corded for the S-h period Chat included both the dose titration
sequence and the COnstant rate infusion .
Through initial randomization, 12 patients were selected
to receive high dose dopexamine. 11 patients intermediate
dose dopexamine, 13 patients low dose dopexamine and 9
patients placebo. However, a total of 10 patients received an
infusion of dopexamme during the
constant
rate
infusion
period that was lower than the infusion rate indicated
through randomization . Dose reduction was intentio,aal in
nine patients because hemodynamic variables in these pa-
tients exceeded the safety guidelines or the patients experi-
enced adverse reactions
. One patient randomized to receive
low dose dnpexamine (I
nggfkg per min) inadvertently
received placebo. Dose reduction from high dose dopesam-
ine (4 pglkg per mini to intermediate dose dopcxaminc
(2 peg/tsp mm) was necessary in five patients The infusion
GULLUR FT At ..
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rate was decreased in three patients because of tachycardia,
in one patient because of nausea and tremor and in one
patient because of agitation and rcstlessncss . Dose reduction
from intermediate to tow dose dnpexamine was necessary in
fhrez patient
., in alt cases because of excessive taehycardia
that responded to a decrease in the infusion rate . To provide
a more accurate appraisal of hemodynamic response
achieved at a given infusion rate, results are reported as to
dose received rather than dose intended .
Statistical anal)sis, All data are expressed as mean values
SD. Far hemodynamic seriahlea, an average of all mea-
sure menu recorded during the 6-h centtant rate infusion was
compared wish a baseline value . The percent change from
baseline r,ri defined as: )(Treatment value - Baseline
value)! faseline
vane)
x W E
Analysis of variance was used to eompare the perecul
change from baseline for each of the four treatment groups .
Hcmody namic trends duringthe 6-h constant infusion period
were tested with use of orthogonal polynomials to calculate
linear and nonlinear regression components. Intake and
output data were analyzed with paired a tests . Differences in
qualitative baseline clinical characteristics between groups
were assessed with Fisher's exact test and quantitative
clinical variables were compared with analysis of variance .
Linear correlation using Spearman s correlation coefficient
was performed to analyze the relation of cardiac index to
both systemic vascular resistance and heart rate in certain
subsets of patients.
Results
Baseline hemodynatttk eh rackristics (Table 2)
. The he-
mod ynamic variables were retractive of patients with severe
congestive heart failure. There were no signifcant differ-
ences in these variables among patients in the four treatmem
groups .
Itemalynamle response m dopcxaminc (Table 3) . An
increase ir. mead cardiac index was observed in each treat-
ment group . Patients mndomiz^.d to receive high dose
dnpexamine experienced a 70% mean increase in cardiac
indes, which was significandy greater in comparison with
values in the othec groups (p-n0.05). The increase in cardiac
i ndcx observed among patients randomized to receive low or
intermediate dose dopexamine exceeded the increase oh-
served for the placebo group, but the difference did not
attain Statistical significance .
Heart rate remained unchanged for the placebo group but
increased for all patients receiving dopexamine (p < 0 .05) .
Systemic vascular resistance decreased in all four groups .
The 43% decrease in systemic vascular resistance observed
in patients receiving high dose dopexamine was significantly
greater than that noted for the other groups (p < 0 .05). Right
atria[, systemic arterial, pulmonary artery and pulmonary
capillary wedge pressures changed minimally from baseline
for each of the four groups. In comparison with other
groups, patients receiving high dose dopexamine showed a
186
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Table 2. Comparison of Baseline Hemodynamic Variables of the Four Patient Groups
greater reduction in pulmonary vascular resistance and
greater increases in stroke work and stroke volume index
(p < 0 .05).
Despite the multicenter design of this trial, the study
lacked sufficient power to detect statistically significant
differences among the four treatment groups unless the
difference was very large . Anticipating this, before initiating
the study, the investigators agreed to consider the contrast
of the average response of the groups assigned to the two
higher doses ofdopexamine versus the response of the group
receiving placebo as one of the primary hemodynamic end
points . The major drawback of this approach is that it could
tend to spread statistical significance achieved by the high
dose group over the intermediate dose group . Its major
advantage is to provide additional information concerning
informal dose ranging (2 to 4
4g/kg
per min) when the power
of a study is limited because of the number of patients
enrolled .
When this contrast analysis is performed, the average
C1= cardiac index; HR hearS role; MAP = muon arrrelat pressure ; MPAP mean pulmonary carry pressure .
PCWP = pulmonary capillary wedge pressure : PVR = pulmonary vascular resistance : RAP = right atria) pressure :
SVI = stroke volume index ; SVR = systemic vauular resistance ; SWI =
stroke work index .
response of the combined intermediate and high dose groups
versus placebo achieved statistical significance (p < 0.05) for
the hemodynamic variables of cardiac index and heart rate.
Among the 35 patients receiving any dose of dopexamine,
linear correlation revealed a strong relation between a de-
crease in systemic vascular resistance and an increase in
cardiac index (r = -0 .96, p < 0
.0001). There was no
significant correlation between cardiac index and head rate
(r = 0.20) .
Hemodynamtc trend analysis during the rnostnnt rate
infusion period
. Serial hemodynamic data for the variables
of cardiac index, heart rate and systemic vascular resistance
were tested for evidence of attenuation during the constant
rate infusion period . At the start of the constant rate infu-
sion, patients had been receiving a set dose for ! h . During
the constant rate infusion, data collection was performed at
the start of the constant rate period and then every 2 h .
Therefore, there were four data points available for trend
analysis
. Trend analysis revealed a significant decrease in
Table 3 . Comparison of Mean Percent Changes From Baseline in Hemodynamic Variables During
the Double-Blind Infusion
'p < 0.05 high e- emus placebo
;
tp < 0 .05
high dose versus low dose;'ip < 0 .05 high dose versus inmrmediate
dose ; III, < 0.05 low dou versus placebo; 4p < 0 .05 intermediate dose versus placebo . Abbreviations as in Table
2 .
JACC Vet . In, No . 2
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Placebo
In = 10)
Low Dose
Dopesamine
In = 151
Inmm:ediate
Dose
Dope-me
(n = 13)
High Dose
Dopn,wn ne
(n =
7)
CI ;liters/min per m11 1 .7 0 0 .3 2 .1!0.3 1 .7 1 .8!0.4
HR Ibeatslminl 90 x 13 84 x 16 95 ! 16 83 n 16
MAP Imm Hgl 99 x 16 92 x II 89 - 12 92 - 16
RAP (mm Hg) 13 x 5 13v6 14x10 IS 1 8
MPAP (mm Hg) 36 x 11 40±8 41!8 36 *-8
PCWP (em Hg) 24 :5 25x5 29x0 2607
SVR Idynesrcm - ' I 2,116 x 484 1,604 _ 230 1,817 x 747 1 .789 _ 591
PVR Idynerscm - ' I t22 x 207 314 x 115 294 x 124 241 _ 93
SVI Im11m21 20 e 4 26x7 19x7 23!8
SWI (g•m/m') 21 . 8 2409 15x7 21±11
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7
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3ACC Vol. I8 . No. 2
August 1991 :35340
cardiac index during the constant rate infusion only for the
intermediate dose group (p < 0.05 for both linear and
nonlinear regression) . There was no evidence of attenuation
for heart rate or systemic vascular resistance for any of the
four groups.
Comparison of fluid intake and output during baseline and
infusion periods (Table 4) . Mean fluid intake and output
were similar for all groups during the 8-h baseline period .
Fluid intake increased in all four groups during the 8-h
randomized infusion period . Urinary output increased to a
lesser degree so that all four groups showed a positive fluid
balance (intake greater than output) during the randomized
infusion period. In comparison with the baseline period, the
increase in fluid balance during the randomized infusion
period (net fluid retention) was most striking for the patients
receiving placebo (net difference 64 ml/h), but did not
approach statistical significance in comparison with the
dopexamine groups.
Adverse reactions. Adverse reactions were uncommon
Turing this study . There were
rare instances of tremor,
nausea and headache . Only one patient developed supra-
ventricular tachycardia possibly related to dopexamine ad-
ministration. In this patient, who had a prior history of
intermittent paroxysmal supraventricular tachycardia, the
supm:entricalar rachyeardin began 4 .81 h after the start of
low dose infusion and persisted for 2 min, with a peak rate of
175 beats/min . The episode terminated spontaneously and no
dose titration of dopexamine was requited .
.Hyporension was noted in only one patient. Mean arte-
rial pressure decreased to 66 mm Ng in a patient receiving
tow dose (1 pg/kg per min) dopexamine . The hypotensivc
episode lasted only 15 min and abated promptly after the
infusion was discontinued .
Only one patient (intermediate dose group) developed
chest discomfort during the study . The chest discomfort
persisted for 15 min and was not strongly suggestive of
angina pectoris . The infusion rate was decreased to I µg/kg
per min and the patient continued in the study without
further episodes of chest discomfort .
GOLLUB ET AL.
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Table 4. Comparison of Fluid Intake and Urinal y Output During Baseline and Infusion Periods
Ventricular arrhythm .as posed no problem during this
study. No patient required dose titration because of a ven-
tricular arrhythmia . Ventricular ectopic activity was aver-
aged over baseline and constant infusion periods . Median
summary values for each group revealed no premature
ventricular beats for the placebo group at baseline or during
infusion, no premature ventricular beats fat the low dose
dopexamine group at baseline and increasing to 1 .5 prema-
ture ventricular beatsimin during infusion, no premature
ventricular beats for the intermediate dose group at baseline
and increasing to 0.251min during infusion and 2 .21min for
the high dose group at baseline and decreasing to I/min
during infusion . Because of the paucity of nonzero data, this
variable was not analyzed by any formal statistical proce-
dure .
Despite the low incidence of serious adverse reactions
end the absence of serious ventricular arrhythmias, it is
important to emphasize that only a few patients had a prior
history of angina or myocardial infarction and that dose
reduction was necessary in nine patients because of changes
in hemodynamic variables (including heart rate) beyond
preestablished limits of safety .
Discussion
Summary of resuhs. The randomized, parallel, placebo-
controlled, double-blind design of this study allows direct
comparison of dopexamine hydrochloride in varying doses
with placebo, Analysis with a placebo control group is
important to accurately characterize the heroodynamic prop-
erties of this medication . Clinical trials that are open label or
that lack a placebo control group may provide helpful
observational data but are insensitive to spontaneous diurnal
variations that occur in hemodynamic variables in hospital-
ized patients. This is the first report that utilizes optimal
clinical trial design characteristics in detailing the hemody-
namic effects of dopexamine in a large group of patiehts with
heart failure .
In this study after dose titration, patients received either
Race50
m=101
Low Dose
Uopenamine
(n i ;1
Intermediate
Dose
Uoposamine
(n = 12)
High Dose
Dopexamine
In = 6)
80881Ine period (.I hi
Mean fluid intake 60 s 20 66 0 33 59 s 28 66 0 20
Mean obey output 57 s 25 67510 57229 52245
Netlntake-ourpu : 3 s 36 -1 s 98 2 s 31 11 2 53
InNsion period (vih)
Mean fluid intake 141 i 62 121 '_ 46 129 a 39 109 2 3R
Mean urinary output 74 0 18 93045 ga±42 040(6
Nei inykvoutpm 67 71 27 •. 55 41 a 46 26 45
Notdifernrwr between 64 x 71 28 : 75 39 s 60 12 164
infusion and baseline
po,ind, Imtm)
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a 6-h constant dose intravenous infusion of placebo or ore of
three doses of dopexamine fl . 2 or 4 gglke per min)
. Only
patients receiving the higher dose of dopexamine (4 pglkg
per min) had a significantly greater increase in cardiac index .
A significant difference in high dose effect versus placebo
was also noted for the heart rate, systemic vascular resis-
tance, pulmonary vascular resistance, stroke volume index
and stroke work index. Responses of patients in the low and
intermudiatc dose cutups differed significantly from those of
patients receiving placebo only for heart rate . None of the
dopexamine groups differed from the placebo group with
reference to mean right atrial, systemic arterial, pulmonary
artery or pulmonary capillary wedge pressure .
The implications
of the study are that shat-term admin-
istratinn of dopexamine at orate of4 pglkg per min produces
a marked (78%) increase in cardiac index associated with a
significant (43%) reduction in systemic vascular resistance
and a moderate (24%) increase in heart rate . At lower doses,
a moderate increase in cardiac index is noted . which does
not reach statistical significance . Facilitation of dieresis was
not observed in any of the treatment groups receiving
dopexamine .
Comparison with other studies . The hemodynamic profile
of dopexamine hydrochloride in patients with congestive
heart failure has previously been described . although previ-
ous study designs did not include a placebo control group .
Jaski and Peters (IS) reported a 65% increase in cardiac
index associated with a 49% decrease in systemic vascular
resistance and a 27% increase in heart rare after the short-
term (10 min) infusion of dopexardne ate dose of 4 pgrkg per
min .
A similar response was noted by Colardyn and Van .
denhogaerde (19) in nine patients 15 rain after titration to a
dose of 4l gglkg per min. Cardiac index increased by 81% and
heart rate by 237 ; systemic vascular resistance decreased
by 39%o . The pattern of response described by these inves .
tigators for the hemodynamic variables of cardiac index .
systemic vascular resistance and heart rate is very similar to
that in the present study.
The effect of dopexamine on right atria), systemic arte-
rial pulmonary artery and pulmonary capillary wedge pres-
sures is less clear . Jaski and Peters 1181 reported a decrease
in right atrial and pulmonary capillary wedge pressures of
10% (p = NS) and 22% (p < 0 .01), respectively . Demarco et
al . (20) reported herradynamic measurements in 10 patients
15 min after
-optimal"
dose titration. Seven patients were
titrated to 6 ;*kg per min . two patients to 4 pglkg per min
and one patient to 2 pg4tg per min . Right atnal pressure
decreased by 25% (p < 0 .01) and pulmonary capillary wedge
pressure by 26% (p < 0 .65). Dawson et al. (3) in an open
label trial observed significant decreases in left ventricular
end-diastolic pressure
(p
< 0 .011 and right atria) pressure
(p < 0
.05) 5 min after ti:rUY.on to doses of 3 and 6 pgrkg per
min .
Only minimal changes in mean right atria), systemic
arterial, pulmonary artery and pulmonary capillary wedge
pressures were observed in "1e present study. In patients
rACC Vol . It. No. 2
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receiving high dose dopexamine, right atria) and pulmonary
capillary wedge pressures decreased by only 12% and 14%,
respectively (p
-
NS versus values in the placebo group)
.
The 10% decrease in pulmonary capillary wedge pressure
observed in patients receiving placebo demonstrates the
importance of a placebo control group in a clinical trial
designed to characterize the hemodynamic profile of a new
vasodilator or inatropie medication .
In our study, patients randomized to receive dope^.amiae
failed to show enhanced dieresis . Lever et al . (6) previously
reported that administration of both low dose (0 .25 to
I pgtkg per min) and high dose (I to 4 poll per min)
dopexamine increased urinary output (p < 0 .1) over a 6•h
infusion period. Urinary sodium excretion also increased in
both treatment groups but was greater in the group receiving
high dose dopexamine . However, an increase in renal blood
flow was noted only for the group receiving tow dose
dopexamine .
In another study reported by Jamison et al . (21), patients
received dopexamine in maximally tolerated doses utilizing
an open label protocol . Renal plasma flow determined by the
p-aminohippurte infusion technique and glomerular filtra-
tion rate determined by imrlin clearance showed no signifi-
cant increase over baseline values
. The dopaminergic clini-
cal effects of dopexamine, which should
be favorable in
patients with congestive heart failure by promoting increases
in renal blood flow, glomerular filtration rate, urinary output
and sodium excretion, remain to be convincingly demon-
strated.
Dose sekclion. Although dopexamine administration at
an infusion rate of 4 pglkg pen min produces a marked
increase in cardiac index, 5 of 12 patients randomized to
receive high dose dopexamine required dose reduction.
Similarly, Colardyn and Vandenbogaerde (19) reported that
3 of 12 patients could not be titrated to doses >2 pglkg per
min
because of vomiting and tachycardia. Lever et al . (6),
using dose titration, found that only 9 of 12 patients could be
advanced to an infusion rate of 2 pglkg per min and only 4
patients could be titmled to 4 pgfkg per min without violating
safety guidelines . These findings are in agreement with our
observations and indicate that dose titration to an infusion
rate of a4 pglkg per min should be undertaken with extreme
vigilance and careful monitoring .
Establishing a role for dopexamine. Although dopexam-
ine possesses a unique spectrum of pharmacalogic activity,
it is unlikely to gain acceptance unless it can be shown to
offer a clinical advantage over available inotropic or vasodi-
lator agents . The most promising attribute of dopexamine is
its dopaminergic activity (22-24) . Although dopexamine
offers a comparable but not superior hemodynamic profile to
that of dobutamine (5,8,tS,25-27),itis conceivable that the
DA,-dopalninergie activity of dopexamine could produce a
greater increase in renal blood flow and natriuresis (28) .
This, however, remains to be
convincingly established and
would be an excellent subject for a large multicenter trial of
appropriate design. The combination of adrenergic activity
)ACC Vol. Is , No . 2
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producing hemodynamie effects similar to those of
dohu-
tamine and dopaminergic activity similar to that of low dose
dopamine could give dopexamine a favorable and unique
application (29) .
The issue of Iolerance produring an u rrenoarion of hemo-
dynamic effect over lime wilt also need to be addressed .
Palients with decompcnsated congestive heart failure fro,
quendy need support for prolonged periods of time tier
example, while awaiting heart transplantation) . Some inves-
tigators (12,14) using open label study designs have already
noted tolerance in association with dnpexamine administrd-
tion . Tread analysis during the &h constant rate infusion in
this study showed an attenuation of effect for cardiac index
in the intermediate dose group. Excessive tolerance, if
corrobara(cd in future studies of prolonged infusion dura •
lion, would pose a substantial limitation to the use of
dopexamine.
Conclusions. This study provides the first results detail-
ing the hemudynamic features of dopexamine utilizing a
multicenter, parallel, placebo-controlled design . ilopexam-
ine at a dose of 4 ag)kg per min produce, a striking increase
in cardiac index largely related to vasodilation . A more
moderate effect is observed at lower doses. In comparison
with placebo, dopexamine failed to produce a significant
reduction in right atria) or pulmonary capillary -wedge pres-
sure . Further studies are indicated to characterize
ibis
medication and provide additional information concerning
its comparative attributes with respect to other inutropic and
vasodilator medications .
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